Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide.

@article{Buckwalter2005PopulationPA,
  title={Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide.},
  author={Mary Buckwalter and James A. Dowell},
  journal={Journal of clinical pharmacology},
  year={2005},
  volume={45 11},
  pages={1279-87}
}
Dalbavancin is a lipoglycopeptide antibiotic in clinical development as a once-weekly treatment for serious infections. A total of 532 patients, consisting of 502 patients with skin and soft tissue infections requiring parenteral therapy and 30 patients with catheter-related bloodstream infections, was available for population pharmacokinetic analysis. The majority of patients (78.4%) received dalbavancin intravenously as a 1000-mg dose on day 1 and a single 500-mg dose on day 8. A 2… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

Dalbavancin: a new lipoglycopeptide antibiotic.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists • 2008
View 6 Excerpts
Highly Influenced

[Evaluation of clinical evidence for dalbavancin].

Enfermedades infecciosas y microbiologia clinica • 2017
View 1 Excerpt

Dalbavancin for the treatment of paediatric infectious diseases

European Journal of Clinical Microbiology & Infectious Diseases • 2016
View 3 Excerpts

Similar Papers

Loading similar papers…